Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide.

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Unfortunately, that's been the case for longer term Pfizer Inc. (NYSE:PFE) shareholders, since the share price is down 55% in ...

Pfizer stock inched down Tuesday on a mixed first-quarter report. Sales missed, but cost cutting led to strong earnings.

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock a strong buy ahead of earnings.

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Pfizer is deeply undervalued, and has a high dividend yield, and I see tons of institutions and analysts buying the dip. Read ...

Pfizer's $13.7 billion in revenue (an 8% decline) and adjusted diluted EPS of $0.92 (12% growth) allowed the firm to maintain its full-year guidance of $61 billion-$64 billion in revenue and $2.80 ...